BridgeBio Pharma Inc (NAS:BBIO)
$ 30.09 -0.95 (-3.06%) Market Cap: 5.63 Bil Enterprise Value: 7.02 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 50/100

BridgeBio Pharma Inc at JPMorgan Healthcare Conference Transcript

Jan 09, 2023 / 11:00PM GMT
Release Date Price: $7.45 (+0.81%)
Anupam Rama
JPMorgan Chase & Co, Research Division - VP and Analyst

All right. Let's go ahead and get started. So this is a Monday afternoon of the 41st Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by Malcolm Kuno and Priyanka Grover from the team. Our next presenting company is BridgeBio and presenting on behalf of the company, we have CEO, Neil Kumar. Neil.

Neil Kumar
BridgeBio Pharma, Inc. - Co-Founder, President, CEO & Director

Thanks, Anupam, and thanks to Phil and the JPMorgan team for having us back to present here. Thanks, everyone, here for [bringing] the tough weather and for those listening in. I'm going to spend the next 20 minutes or so talking about BridgeBio Pharma, a company that aspires to be a leader in the area of genetic medicine. We arrived here at the beginning of 2023, once again at the doorstep of profound advancement both for the patients that we serve as well as for investors, most notably due to 2 key readouts we have upcoming in the first

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot